{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-022360","form_type":"8-K","ticker":"CING","cik":"0001862150","company_name":"Cingulate Inc.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.425662+00:00","generated_at":"2026-05-17T19:57:18.986525+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cingulate submits NDA to FDA for lead ADHD drug CTx-1301","bullets":["Submitted NDA on July 31, 2025 for CTx-1301 (dexmethylphenidate) for ADHD.","FDA will decide on acceptance within 60 days of July 31 submission.","Drug designed as novel extended-release tablet for once-daily, entire active-day symptom control.","Cingulate targets $23B U.S. ADHD market; over 20M patients diagnosed in US.","NDA is first regulatory application of company's proprietary Precision Timed Release platform."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-022360","json":"https://secwatch.observer/filing/0001641172-25-022360.json","markdown":"https://secwatch.observer/filing/0001641172-25-022360.md","text":"https://secwatch.observer/filing/0001641172-25-022360.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1862150/000164117225022360/0001641172-25-022360-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1862150/000164117225022360/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:57:18.986525+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}